This Medudy course is a video tutorial for physicians on the topic of "Drug-drug interactions (DDIs) during ARPI administration in the context of advanced prostate cancer therapy."
Prof. Axel Merseburger, Director of the Department of Urology at the Lübeck Campus of the University Medical Center Schleswig-Holstein, presents the current evidence and clinical relevance of this topic.
This is particularly important because the patients affected often have several age-related comorbidities that require treatment. The interactions arise primarily through induction or inhibition of the cytochrome P450 system. The evidence analysis is based on two recent reviews, including publications by Ibáñez C et al. (2025) and Bolek H et al. (2024). The knowledge conveyed here about these pharmacokinetic interactions is essential for avoiding undesirable side effects in practice.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
The course was developed with the kind support of Bayer.
At the end of this training you will know:
- The clinical relevance of drug-drug interactions (DDIs) among androgen receptor pathway inhibitors (ARPIs) in patients with prostate cancer.
- the central pharmacokinetic mechanisms of DDI, in particular the role of the cytochrome P450 system.
- the different interaction potentials of the various ARPIs (apalutamide, enzalutamide, and darolutamide) on CYP isoenzymes.
- the current evidence and the resulting implications for clinical practice to avoid undesirable side effects.
